Abstract
Neoadjuvant chemohormonal therapy prior to prostatectomy in high-risk prostate cancer-is biochemical recurrence an adequate surrogate marker for clinical benefit?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have